Last reviewed · How we verify
Lipofundin MCT 20%
Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.
Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally. Used for Parenteral nutrition in patients unable to maintain adequate oral or enteral intake, Prevention of essential fatty acid deficiency during prolonged parenteral nutrition, Nutritional support in post-operative and critically ill patients.
At a glance
| Generic name | Lipofundin MCT 20% |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Lipid emulsion; parenteral nutrition supplement |
| Modality | Small molecule |
| Therapeutic area | Nutrition support; Critical care |
| Phase | FDA-approved |
Mechanism of action
This intravenous lipid emulsion contains a mixture of medium-chain triglycerides (MCT) and long-chain triglycerides (LCT) that serve as an energy source and provide essential polyunsaturated fatty acids. It is administered as part of total parenteral nutrition (TPN) to support metabolic needs, maintain nutritional status, and prevent essential fatty acid deficiency in critically ill or post-operative patients.
Approved indications
- Parenteral nutrition in patients unable to maintain adequate oral or enteral intake
- Prevention of essential fatty acid deficiency during prolonged parenteral nutrition
- Nutritional support in post-operative and critically ill patients
Common side effects
- Hypertriglyceridemia
- Infusion site reactions (phlebitis, thrombophlebitis)
- Hypersensitivity reactions
- Hepatic dysfunction
- Pancreatitis
Key clinical trials
- The HOME Study (HPN With OMEGA-3) (PHASE4)
- Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants (PHASE2)
- Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery (NA)
- Lipid Emulsions and Liver Function - Results After 5 Years. (PHASE4)
- Different Lipid Emulsions in Acute Lung Injury Patients (PHASE4)
- Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients (PHASE2)
- Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study (PHASE4)
- The Impact of Immunostimulating Nutrition on the Outcome of Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipofundin MCT 20% CI brief — competitive landscape report
- Lipofundin MCT 20% updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI